Technical Analysis for NBIX - Neurocrine Biosciences, Inc.

Grade Last Price % Change Price Change
grade A 109.87 -0.94% -1.04
NBIX closed down 0.94 percent on Thursday, November 14, 2019, on 1.21 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical NBIX trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
Overbought Stochastic Strength 0.00%
Slingshot Bullish Bullish Swing Setup -0.94%
Calm After Storm Range Contraction -0.94%
Upper Bollinger Band Walk Strength -0.94%
Multiple of Ten Bullish Other -0.94%
Overbought Stochastic Strength -0.94%
New 52 Week Closing High Bullish -1.37%
Calm After Storm Range Contraction -1.37%

Older signals for NBIX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Chemistry Pain Diabetes Disorders Schizophrenia Alcohols Cardiovascular Diseases Hormones Epilepsy Ethers Movement Disorders Ii Diabetes Pyrimidines Gnrh Antagonists Endometriosis Gonadotropin Releasing Hormone Antagonist Insomnia Uterine Fibroids
Is NBIX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 113.12
52 Week Low 64.72
Average Volume 695,927
200-Day Moving Average 88.409
50-Day Moving Average 97.2852
20-Day Moving Average 102.323
10-Day Moving Average 106.797
Average True Range 3.4327
ADX 40.51
+DI 33.0357
-DI 10.4967
Chandelier Exit (Long, 3 ATRs ) 102.8219
Chandelier Exit (Short, 3 ATRs ) 102.7181
Upper Bollinger Band 112.9802
Lower Bollinger Band 91.6658
Percent B (%b) 0.85
BandWidth 20.830507
MACD Line 4.2028
MACD Signal Line 3.2106
MACD Histogram 0.9922
Fundamentals Value
Market Cap 9.69 Billion
Num Shares 88.2 Million
EPS -2.52
Price-to-Earnings (P/E) Ratio -43.60
Price-to-Sales 826.51
Price-to-Book 15.16
PEG Ratio 1.78
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 114.54
Resistance 3 (R3) 114.52 112.95 113.76
Resistance 2 (R2) 112.95 111.76 112.96 113.50
Resistance 1 (R1) 111.41 111.03 110.63 111.43 113.24
Pivot Point 109.84 109.84 109.45 109.85 109.84
Support 1 (S1) 108.30 108.65 107.52 108.32 106.50
Support 2 (S2) 106.73 107.92 106.74 106.24
Support 3 (S3) 105.19 106.73 105.98
Support 4 (S4) 105.21